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Transient complementation of human cytomegalovirus (HCMV) oriLyt DNA replication in permissive human diploid cells
expressing replication genes under native promoters requires its UL36-38 gene products. Two of the immediate early (IE)
proteins encoded by this locus, pUL37x1 and, to a lesser extent, gpUL37, activated expression of HCMV early gene promoter
constructions. The other IE protein encoded by the UL36-38 locus, pUL36, and the early product, pUL38, did not transactivate
the HCMV early promoter constructions under similar conditions. The acidic domain, common to both pUL37x1 and gpUL37,
is required for activation of HCMV early promoter constructions. Conversely, gpUL37 sequences downstream of amino acid
199 are not required for transactivation of viral early promoters. Taken together, these results suggest that the requirement
for UL36-38 products for HCMV DNA replication results, at least in part, from the requirement of the transactivation of HCMV
early DNA replication promoters by pUL37x1 and, to a lesser extent, by gpUL37 and that the acidic domain is critical for this
activity. © 1998 Academic Press
INTRODUCTION
Although similar to alphaherpesvirus DNA replication,
human cytomegalovirus (HCMV) oriLyt DNA replication
appears to be more complex as its origin spans 2.4 kbp
and requires 11 distinct genetic loci as determined in
transient assays (reviewed in Anders and McCue, 1996).
Among the required loci are 3 immediate early (IE) loci,
which do not encode replication fork proteins and in-
clude the UL36-38 locus (Pari and Anders, 1993; Pari et
al., 1993).
The UL36-38 locus is complex in that it encodes at
least four transcripts; the UL36, UL37, and UL37x1/38
RNAs are IE in temporal expression, whereas the UL38
RNA is an early product (Fig. 1A, Wilkinson et al., 1984;
Kouzarides et al., 1988; Tenney and Colberg-Poley,
1991a,b; reviewed in Colberg-Poley, 1996). Antisense ex-
periments are consistent with the requirement for UL36
and UL37 gene products for HCMV growth and DNA
replication (Smith and Pari, 1995; Pari et al., 1995). The
dependence upon UL36-38 products for HCMV oriLyt
DNA replication is lost by the presence of UL69 in Vero
cells but not in permissive human diploid fibroblasts
(HFF) (Sarisky and Hayward, 1996).
The products of the IE transcripts include the UL36
protein (pUL36), a member of the US22 family (Chee et
al., 1990), the UL37 exon 1 protein (pUL37x1), and the
UL37 N-glycoprotein (gpUL37). pUL36 does not share its
sequences with any of the other UL36-38 products. In
contrast, gpUL37 and pUL37x1 proteins are encoded by
partially overlapping transcripts and share the amino-
terminal 162 amino acids (aa) of their respective open
reading frames (ORF, Fig. 1B). Their common features
include a hydrophobic signal sequence (aa 1–22) and a
strongly charged acidic domain (aa 81–108). Unique to
gpUL37 are 17 N-glycosylation sites, a basic domain, a
transmembrane/anchor sequence, and a cytosolic tail
(Kouzarides et al., 1988; Chee et al., 1990). gpUL37 is
synthesized in the HCMV-infected cell as a type I mem-
brane-bound protein, traffics through the endoplasmic
reticulum and Golgi apparatus, and is modified by N-
glycosylation within 2 h of synthesis (Al-Barazi and Col-
berg-Poley, 1996). It does not detectably colocalize with
the HCMV major IE protein 1 (IE1) (Zhang et al., 1996).
The aforementioned requirement for UL36-38 products
for HCMV oriLyt DNA replication may result from their
regulatory activities. Similarly to most HCMV IE proteins,
pUL36, pUL37x1, and gpUL37 have nuclear regulatory
activity as demonstrated by regulation of a human heat
shock protein 70 (hsp70) promoter construction (Colberg-
Poley et al., 1992; Tenney et al., 1993; Zhang et al., 1996).
Consistent with these findings, a genomic construction
spanning the HCMV UL33-38 region was found previ-
ously to transactivate HCMV early promoter construc-
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tions (Iskenderian et al., 1996). In these experiments, we
determined which of the UL36-38 IE and early proteins
transactivate HCMV early DNA replication gene pro-
moter constructions and which domain in the regulatory
proteins is required for this stimulation.
RESULTS
Our previous results indicate that the UL33-38 region,
encoded by pZP8, contributes significantly to the regu-
lation of HCMV early gene transcription (Iskenderian et
al., 1996). To determine whether the UL36-38 IE region
contained within this genomic construction encodes the
proteins required for this regulation, we tested deletion
mutants of the UL33-38 genomic clone for regulation of
the HCMV UL54 promoter (Fig. 2). As found previously,
the combination of TRS1, pUL84, IE1, IE2, and UL112-113,
referred to hereafter as All, with the genomic clone
UL33-38 (All (UL33-38)) transactivated the UL54 pro-
moter. This value of transactivation was taken as 100%.
Cells transfected with deletion of the genomic UL33
locus (All (UL34-38)) or of the UL34-35 (All (UL33, 36-38))
ORFs produced 212.9 6 33.3 and 107 6 5.2%, respec-
FIG. 1. The products of the HCMV UL36-38 locus. (A) The UL36-38 transcripts. The UL36-38 locus spans nt 52,706 to 48,246 of the HCMV genome.
The alternatively spliced transcripts encoded by the region are shown as are their respective sizes and kinetic class. The bent arrows represent the
promoters within the locus and the exons (filled boxes) and introns (strippled boxes) are indicated. (B) The wild-type and mutant pUL37x1 and gpUL37
proteins. Shown are the amino-terminal sequences (aa 1–162) common to both pUL37x1 and gpUL37. These include the hydrophobic signal sequence
(aa 1–22, coil) and acidic domain (aa 81–108, open box). pUL37x1 as one additional amino acid. Unique to gpUL37 (aa 163–487) are a large
N-glycosylation domain (aa 206–391, branches), a transmembrane (aa 433–459, coil), and cytoplasmic domains (aa 460–487). The mutants lacking the
acidic domain (pUL37x1 Daa 53–140 and gpUL37 Daa 53–140) are shown as are the gpUL37 truncation mutants, gpUL37 aa 1–199 and gpUL37 aa
1–461.
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tively, and, therefore, had no reductive effect on UL54
regulation. The simultaneous deletion of UL33, 34, 35
ORFs (All (UL36-38)) had a modest effect on UL54 regu-
lation, reducing this value to 55.9 6 10.2%. However,
deletion of the UL36-38 ORFs (All (UL33-35)) abrogated
regulation of the UL54 promoter reducing the relative
value to 4.8 6 0.7%. This value was similar to that (3.8 6
1.4%) obtained in the absence of the complete UL33-38
construction (All (2UL33-38)). We conclude, therefore,
that the UL36-38 region is largely responsible for the
cooperative activation of HCMV early gene promoters by
the products of the UL33-38 locus.
To determine which of the UL36-38 products was re-
sponsible for the transactivation, we tested the pooled
UL36, UL37x1/38, UL37, and UL38 cDNAs in combination
with All (Fig. 3). For these experiments, we show trans-
activation of the srt and UL57 promoter constructions.
However, similar results were obtained with the UL44,
UL54, and UL112-113 promoter constructions (unpub-
lished observations). Combination of All with the pooled
UL36-38 cDNAs (All (UL36-38 cDNAs)) provided 100 6
37.2 and 100 6 30.4% for the srt and UL57 promoter
constructions, respectively. Removal of only the UL37x1/
UL38 cDNA (All (2UL37x1/38)) abrogated activity as the
relative conversion was reduced to 5.0 6 1.5% (srt pro-
moter) and 10.2 6 4.8% (UL57 promoter). Similarly, cells
transfected with All and an acidic domain deletion mu-
tant of pUL37x1 (All (UL37x1 Daa 53–140) had reduced
activity for both the srt (10.5 6 7.0%) and UL57 (10.1 6
6.4%) promoter constructions. In contrast, deletion of the
UL38 ORF (All (UL37x1), 86.27 6 83.1, 93.8 6 33.6%) or its
truncation (All (UL37x1/UL38 stop), 88.0 6 11.9, 69.4 6
6.0%) did not reduce activity of the encoded proteins.
Thus, pUL37x1 activated the expression of the HCMV
early gene promoter constructions. In particular, these
results implicate the pUL37x1 acidic domain as being
critical for the regulation of HCMV early gene promoters.
To determine whether any individual UL36-38 cDNA is
sufficient to replace the genomic UL33-38 construction,
we tested addition of each individual cDNA in the All
mixture (Fig. 4A). Addition of the pUL37x1/38 cDNA (All
(UL37x1/38)) had the most marked stimulatory effect,
providing about 62.4 6 10.2% of the activity of the total
genomic control (All (UL33-38), 100 6 11.1%), while the
gpUL37 had a modest but notable and consistent effect
(18 6 3.8%) on the UL44 promoter construction. Addition
of either pUL36 (All (UL36), 6.7 6 0.5%) or pUL38 (All
(UL38), 7.2 6 2.9%) expression clones did not have a
measurable stimulatory effect on UL44 gene expression.
Thus, transactivation of the HCMV early UL44 gene pro-
moter construction by UL33-38 results predominantly
from the transactivation effect of pUL37x1 and, to a
lesser degree, from that of gpUL37.
Transfection of the individual pUL37x1 or gpUL37
expression clones, in the absence of other HCMV
regulatory proteins, provided a minimal transactivation
of the HCMV UL44 promoter construction (Fig. 4B).
pUL37x1 and gpUL37 increased the expression of the
UL44 promoter construction 0.5 6 0.1 and 0.3 6 0.0%,
respectively. These levels were about two- to threefold
FIG. 2. Transactivation of the HCMV UL54 promoter construction by
UL36-38 gene products. HFF cells were lipofected with pAI13 (UL54
promoter), All (TRS1, UL84, IE1, IE2, and UL112-113 expression vectors),
and the genomic constructions encoding UL33-38 (pZP8), UL36-38
(pAI9, DUL33-35), UL34-38 (pAI10, DUL33), and UL33, 36-38 (pAI11,
DUL34, 35). Control cultures were transfected with pAI13 and All only
(All (2UL33-38)). Cells were harvested 96 h after lipofection and as-
sayed for luciferase activity. Shown is a representative experiment with
the averages of triplicate samples. The error bars indicate standard
errors of the means.
FIG. 3. Mutations in pUL37x1 eliminate transactivation, but mutations
in pUL38 have minimal effect. HFF cells were lipofected with luciferase
expression vectors pLHB135 (srt promoter) or pLHB2 (UL57 promoter)
and All (TRS1, UL84, IE1 and 2, UL112-113) as well as the pooled
UL36-38 cDNAs (All (UL36-38 cDNAs)) or with the pooled cDNAs but
without the UL37x1/38 cDNA (All (2UL37x1/38)). Mutant constructions
lacking the acidic domain (UL37x1Daa 53–140), or the UL38 ORF
(UL37x1), or with a truncation of the UL38 ORF (UL37x1/38 stop) were
used in place of the wild-type UL37x1/38 cDNA. Control cultures were
transfected with the respective luciferase expression vector alone
(none). Shown is a representative experiment with the averages of
triplicate samples. The error bars indicate standard errors of the
means.
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less than the combined effect of IE1 and IE2 (1.1 6
0.4%) on the UL44 promoter construction. No regula-
tion was observed following transfection with the
UL36 (0.1 6 0.01%) or UL38 (0.1 6 0.01%) expression
vectors when compared to addition of no expression
vector (none, 0.1 6 0.01%).
The degree of regulation was greatly increased by
the combination of the pUL37x1 expression vector and
the IE1 and IE2 expression vector (Fig. 4C). Synergistic
activation of the UL44 gene promoter construction is
observed between the MIE IE1 and IE2 proteins and
pUL37x1 (28.2 6 1.6%) and, to a lesser degree, with
gpUL37 (9.8 6 1.6%). While no synergism of IE1 and
IE2 was observed with either pUL36 (0.2 6 0.1%) or
pUL38 (0.5 6 0.0%). These effects are noted for a
broad spectrum of HCMV early gene promoters, rang-
ing from the candidate srt promoter to those of the
UL44 and UL57 genes. Taken together with those
above, these results suggest that regulation of HCMV
early gene promoters requires multiple IE proteins
from different loci, in particular IE1 and IE2 with
pUL37x1 or gpUL37.
To test the requirement for the gpUL37 acidic domain,
common to gpUL37 and pUL37x1 and found to be critical
for pUL37x1 activity, we tested a gpUL37 acidic domain
deletion mutant for transactivation of the HCMV UL44
gene promoter construction (Fig. 5). This mutant (gpUL37
Daa 53–140) is known to traffic through the secretory
apparatus similarly to wild-type gpUL37 and to retain
most of the wild-type transactivating activity for the
hsp70 promoter construction (Zhang et al., 1996). Wild-
type gpUL37, in combination with IE1 (UL37 1 IE1),
FIG. 4. pUL37x1 transactivates independently and cooperates synergistically with the major immediate early proteins. (A) HFF cells were lipofected
with pAI1 (UL44 promoter construction), All (TRS1, pUL84, IE1, IE2, UL112-UL113), and pZP8 (All (UL33-38)), the indicated individual cDNAs, or without
pZP8 (All (2UL33-38)). Control cultures were transfected with the pAI1 vector alone (none). HFF cells were lipofected with pAI1 (UL44 promoter) and
(B) indicated individual expression vectors or with no additional DNA (none) or (C) with a combination of IE1 and IE2 and the individual indicated
cDNAs. Shown is a representative experiment with the averages of triplicate samples. The error bars indicate standard errors of the means.
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stimulated the UL44 promoter construction about 14.6
(65.5)-fold above the levels observed with vector control
(1.0 6 0.0-fold). This value was increased above either
IE1 (6.6 6 1.0-fold) or gpUL37 (UL37, 2.1 6 0.2-fold) alone.
Deletion of the acidic domain abrogated activity of the
gpUL37 protein alone (UL37 Daa 53–140, 0.7 6 0.2-fold)
or in combination with IE1 (UL37 Daa 53–140 1 IE1,
2.8 6 1.0-fold). Thus, similar to the findings with pUL37x1,
the acidic domain of gpUL37 appears to play a critical
role in transactivation of HCMV early gene promoters.
To determine the requirement for gpUL37 unique
sequences in UL44 early gene promoter transactiva-
tion, a truncation mutant lacking all of the unique
sequences of gpUL37 downstream of aa 199 (gpUL37
aa 1–199) or another lacking the gpUL37 carboxy-
terminal cytosolic tail (gpUL37 aa 1–461) were as-
sayed for their ability to transactivate the UL44 gene
promoter construction in the presence or the absence
of IE1 (Fig. 6). gpUL37 aa 1–199 alone (UL37 aa 1–199,
2.2 6 0.4-fold) or in combination with IE1 (UL37 aa
1–199 1 IE1, 17.0 6 4.4-fold) transactivated the HCMV
UL44 promoter construction to levels comparable to
those obtained with wild-type gpUL37 alone (UL37,
2.1 6 0.2-fold) or with wild-type gpUL37 and IE1
(UL37 1 IE1, 14.6 6 5.5-fold). Use of a gpUL37 mutant
lacking the cytosolic residues produced similar re-
sults. gpUL37 aa 1–461 alone (UL37 aa 1–461, 4.1 6
1.9-fold) or in combination with IE1 (UL37 aa 1–461 6
IE1, 17.0 6 4.4-fold) transactivated the UL44 gene
promoter construction to levels similar to those ob-
tained with the wild-type protein. These results indi-
cate that the unique domains (N-glycosylation, basic,
transmembrane, and cytoplasmic domains) lacking in
these mutants are not necessary for transactivation of
the HCMV early gene promoter constructions.
DISCUSSION
In these studies, we have defined the members of the
UL36-38 products which are capable of cooperative reg-
ulatory interactions in the transactivation of HCMV early
gene promoters. Our results suggest that the require-
ment for UL36-38 proteins for HCMV DNA replication
may result from the ability of pUL37x1 and, to a lesser
extent, of gpUL37 to transactivate HCMV DNA replication
gene promoters. The acidic domain of either of these
proteins appears to play a critical role for these regula-
tory interactions.
HCMV IE loci, including the UL36-38 locus, were
found to be required for HCMV oriLyt DNA replication
when the DNA replication genes were expressed un-
der the control of their own promoters (Pari and
Anders, 1993; Pari et al., 1993). Sarisky and Hayward
(1996) identified a strict requirement for both UL84 and
UL36-38 products in an oriLyt-directed omission as-
say. Nevertheless, the requirement for UL36-38 prod-
ucts, but not UL84, was eliminated by supplementing
the transient assays with ppUL69 in Vero cells.
ppUL69 is a virion protein which localizes to nuclear
compartments and DNA replication compartments and
is presumed to transactivate gene expression broadly
by interacting with a chromatin factor (Winkler et al.,
1994; Sarisky and Hayward, 1996; Winkler and Stam-
minger, 1997). Nevertheless, it was not possible to
replace UL36-38 products in the oriLyt-directed omis-
sion assay in HFF cells, suggesting, in this latter case,
FIG. 5. The gpUL37 acidic domain is required for transactivation of
the UL44 promoter. HFF cells were lipofected with pAI1 (UL44 pro-
moter) and the indicated expression vectors. The cells were harvested
96 h posttransfection and assayed as described under Materials and
Methods. Results show the means and standard errors of triplicate
samples obtained in four independent experiments.
FIG. 6. The unique domain of gpUL37 are dispensable for UL44
promoter transactivation. HFF cells were lipofected with pAI1 (UL44
promoter) and the indicated expression vectors. The cells were
harvested 96 h posttransfection and assayed as described under
Materials and Methods. Results show the means and standard
errors of duplicate samples obtained in four independent experi-
ments.
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incomplete complementation of UL36-38 function by
ppUL69.
The requirement for UL36-38 products during oriLyt
DNA replication appears to result, at least in part, from
the regulatory activities of the pUL37x1 and to a lesser
degree of gpUL37. Based upon their regulatory activ-
ities, it is generally surmised that IE proteins alter the
expression of cellular and viral genes which are re-
quired for the progression of the viral lifecycle. These
studies demonstrate that pUL37x1 and gpUL37 can
regulate HCMV early DNA replication gene promoter
constructions, while the other UL36-38 IE protein,
pUL36, did not. The requirement for such transactiva-
tors in DNA replication could be explained by the need
to efficiently express the HCMV early promoters dur-
ing HCMV DNA replication. The observed dependence
upon cooperative regulator interactions of multiple loci
for the efficient expression of cellular and viral repli-
cation proteins is consistent with our previous results
(Iskenderian et al., 1996).
Although IE1 served as co-transactivator in transac-
tivation of both UL44 promoter and hsp70 promoter
constructions (Zhang et al., 1996), the phenotypes of
the acidic domain and truncation gpUL37 mutants
obtained with the HCMV early promoter constructions
in HFF cells are in marked contrast to those obtained
with the human hsp70 promoter construction (unpub-
lished results). The gpUL37 aa 1–199 truncation mu-
tant in combination with IE1 was inactive in hsp70
promoter transactivation (unpublished results). This
was in spite of the finding that the gpUL37 aa 1–199
mutant retains almost wild-type activity with the HCMV
UL44 gene promoter construction. These results sug-
gest that, in contrast to HCMV early promoters, trans-
activation of the hsp70 promoter construction in HFF
cells does not require the gpUL37 acidic domain
(Zhang et al., 1996) but does require unique gpUL37
sequences.
The pUL37x1 and gpUL37 proteins may act in a
transcriptional or posttranscriptional capacity to acti-
vate expression of core genes. At the level of tran-
scription, they may play a direct or an indirect role
during transcription. We favor an indirect role, as the
requirement for UL36-38 proteins can be overcome by
the addition of ppUL69, in Vero cells, which is thought
to transactivate gene expression by interacting with a
chromatin factor (Sarisky and Hayward, 1996; Winkler
and Stamminger, 1997).
Our previous studies establish that gpUL37 is syn-
thesized as a type I integral membrane protein and is
trafficking through the endoplasmic reticulum and the
Golgi apparatus (Al-Barazi and Colberg-Poley, 1996).
Thus, the acidic domain of gpUL37 is membrane-
bound following synthesis of the primary translation
product. However, the gpUL37 acidic domain could be
released by proteolytic cleavage and translocated to
nucleus. Processing by proteolytic cleavage of a mem-
brane-bound regulatory protein and subsequent trans-
location to the nucleus is known to occur with sterol
regulatory element binding proteins (Sakai et al., 1996).
There is a potential protease site on gpUL37 starting
at aa 416, prior to the TM domain. However, our pre-
vious studies indicate that a large portion of gpUL37
(aa 201–420) is intact and not detectable in the cytosol
by immunoprecipitation using polyvalent antibodies
against the N-glycosylation domain (Al-Barazi and Col-
berg-Poley, 1996). Nevertheless, a small acidic subdo-
main, lacking those epitopes, would not have been
detected by immunoprecipitation. Colocalization stud-
ies using confocal microscopy indicate that the car-
boxy terminus of gpUL37 does not detectably colocal-
ize with the predominantly nuclear IE1 protein (Zhang
et al., 1996).
Although the pUL37x1 is virtually contained within
gpUL37, pUL37x1 is likely to have a different process-
ing and trafficking pattern than that of gpUL37. The
N-glycosylation, transmembrane, and cytosolic do-
mains in gpUL37 are not present in pUL37x1. Local-
ization studies of pUL37x1 in HCMV-infected cells are
confounded by the nearly complete overlap of its ORF
with that of the amino-terminal 162 aa of gpUL37.
However, it is likely that pUL37x1 can enter the nu-
cleus because of its small size and the absence of
anchor sequences. We note that there are several
clusters of basic residues which might serve as nu-
clear localization signals.
Consistent with both proteins having an effect on
HCMV early gene promoter constructions, albeit to a
lesser degree with gpUL37, the acidic domain common
to both of these proteins plays a key role in this regula-
tion. Similarly, the acidic domains of IE2 are required for
its function (Pizzorno et al., 1991).
The pUL37x1/gpUL37 acidic domain may serve to
recruit transcriptional machinery. Acidic activator pro-
teins stimulate transcription by RNA polymerase II by
a mechanism that is conserved among eukaryotic or-
ganisms (Tjian and Maniatis, 1994). Acidic activation
domains can interact in vitro directly with some com-
ponents of the general transcription machinery. These
include the TATA-binding protein, TBP (Ingles et al.,
1991; Stringer et al., 1990), TBP-associated factors
(TAFs), which are components of the TFIID complex
(Goodrich et al., 1993; Hoey et al., 1993), TFIIA (Ozer
et al., 1994), TFIIB (Lin et al., 1991), TFIIF (Joliot et
al., 1995), and TFIIH (Xiao et al., 1994). The acidic
activation domain of Epstein–Barr virus nuclear anti-
gen 2 associates with p100, a cellular protein that
directly interacts with TFIIE (Tong et al., 1995). In
stepwise assembly reaction, acidic activation domains
can stimulate formation of a TFIID–TFIIA–TATA ele-
ment complex, recruitment of TFIIB, and the recruit-
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ment of later acting components (Stargell and Struhl,
1996).
From their studies, Sarisky and Hayward (1996) sug-
gest that UL36-38 proteins stimulate posttranscriptional
events; however, our results showing the quantitatively
differential transactivation of HCMV early promoter–lucif-
erase constructions, which differ only in their promoter
sequences, by gpUL37 argue that the transactivation is
at the level of transcription. Consistent with these find-
ings, a NF-kB-tk promoter–luciferase construction con-
taining the luciferase gene, the SV40 intron, and polyad-
enylation signals, as used in the pGL2-basic vector used
for these HCMV early promoter–indicator plasmids, is
unresponsive to gpUL37 transactivation (unpublished
observations). These results are consistent with gpUL37
transactivating the transcription of the HCMV early gene
promoter constructions.
MATERIALS AND METHODS
Plasmid constructions
Figure 1B shows the wild-type gpUL37 or pUL37x1 mo-
tifs retained by the mutant proteins used for this study. p521
encodes gpUL37 Daa 53–140 and has been previously
described (Zhang et al., 1996). p567 encodes gpUL37 aa
1–199. To generate p567, the UL37 cDNA from p414 (Col-
berg-Poley et al., 1992) was cloned as an EcoRI fragment
into pBSII(SK1) (Stratagene) generating p523. The UL37
ORF was then mutated by the insertion of a stop linker
(59-CTA GGC CTT AGC GGC CGC TAG-39) between the
SnaBI sites [nucleotides (nt) 50,777–50,395] generating
p528. The mutation was verified by DNA sequencing using
the US Biochemical Sequenase kit. The mutant UL37 cDNA
from p528 was subcloned into the p394 expression vector
containing the HCMV MIE promoter (nt 173,678–174,402)
and an SV40 polyadenylation site (nt 2533 to 2770) resulting
in p567. p612 encodes gpUL37 aa 1–461. To generate p612,
p414 DNA was mutated by the insertion of the stop linker
above into the unique NruI site (nt 49,991) in the UL37 ORF.
The construction was verified by nucleotide sequencing.
Plasmid AI9 was made by treating pZP8 (Pari and
Anders, 1993) with XhoI and BglII, blunting the ends with
Klenow, and religating to delete the sequence between
nt 42,045 and 47,366, containing the UL33, UL34, and
most of the UL35 ORFs. Plasmid AI10 was made by
treating pZP8 with XhoI plus NsiI under conditions in
which XhoI cleavage was complete but NsiI cleavage
was partial, gel purifying the fragment singly cut with NsiI
at nt 43,703, blunting with Klenow treatment, and self-
ligating, removing most of the UL33 ORF. Plasmid AI11
was made by treating ZP8 with Bst1107I and XmnI under
conditions in which Bst1107I digestion was complete but
XmnI digestion was partial, gel purifying the plasmid
singly cut with XmnI at nt 45,448, blunting the ends with
Klenow, and self-ligating, deleting portions of the UL34
and UL35 ORFs. Plasmid 327DAgeI was made by treat-
ing p327 (Tenney and Colberg-Poley, 1991a) with AgeI
and self-ligating, removing sequences encoding a 88-
amino-acid segment, including the pUL37x1 acidic re-
gion. Plasmid 327DMluI/NruI was made by treating p327
with MluI plus NruI, blunting the ends, and self-ligating,
deleting the segment extending from nt 51,428 to 51,788
within the UL38 ORF. Plasmid 327MluI/PacI was made by
linearizing p327 with MluI, blunting, and ligating into the
blunted site a phosphorylated oligonucleotide (59-CCT
ACT TAA TTA ATG ACT GAC TGA C-39) containing a PacI
site and stop codons in all six reading frames. Plasmid
LHB135 was made by excising the XhoI to NotI fragment
extending from nt 92,636 to 92,891 from pSP50 (Anders et
al., 1992), blunting with Klenow, and ligating the gel-
purified fragment into the SmaI site of pGL2-basic (Pro-
mega Corp.).
TABLE 1
Effector and Target Plasmids Used in These Experiments
Effector plasmid ORFs Reference
pSVH IE1 and IE2 Stenberg et al. (1990)
pRR59 IE1 Colberg-Poley et al.
(1991)
pZP8 UL33-38 Pari et al. (1993)
pZP24 UL112/113 Pari and Anders (1993)
pZP13 UL84 Pari et al. (1993)
pXEXX-6.1 TRS1 Thomas Jones
(unpublished)
Iskenderian et al. (1996)
pZP3 IRS1 Pari et al. (1993)
pAI9 ZP8DUL33-35 This work
pAI10 ZP8DUL33 This work
pAI11 ZP8DUL33-34 This work
pAI12 ZP8DUL36-38 Iskenderian et al. (1996)
p326 pUL36 Tenney and Colberg-
Poley (1991a)
p327 pUL37x1/pUL38 Tenney and Colberg-
Poley (1991a)
p327DAgeI pUL37x1D aa53-140 This work
p327DMluI/NruI pUL37x1/pUL38 stop This work
p327/MluI/PacI This work
p406 pUL38 Colberg-Poley et al.
(1991)
p414 gpUL37 Colberg-Poley et al.
(1992)
p567 gpUL37 aa 1–199 This work
p521 gpUL37 Daa 53–140 Zhang et al. (1996)
p612 gpUL37 aa 1–461 This work
Target plasmid Promoter–indicator Reference
pLHB135 srt promoter–luc Huang et al. (1996)
pLHB2 UL57 promoter–luc Iskenderian et al. (1996)
pAI1 UL44 promoter–luc Iskenderian et al. (1996)
pAI3 UL70 promoter–luc Iskenderian et al. (1996)
pAI5 UL102 promoter–luc Iskenderian et al. (1996)
pAI7 UL105 promoter–luc Iskenderian et al. (1996)
pAI13 UL54 promoter–luc Iskenderian et al. (1996)
pAI15 UL112-113 promoter–luc Iskenderian et al. (1996)
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Transactivation experiments
Experiments were done essentially as described by
Iskenderian et al., (1996) as either addition or subtraction
protocols, using the indicated target and effector plas-
mids listed in Table 1. Briefly, HFF cells were lipofected
with a total of 1 mg of DNA using Lipofectamine (GIBCO-
BRL, Iskenderian et al., 1996). Cells were harvested in
lysis buffer (Promega, E3971) and assayed for luciferase
activity using Promega reagents (E1483). The production
of photons was measured using either a beta scintilla-
tion counter with the coincidence counting circuit turned
off or a beta scintillation counter with a Single Photon
Monitor (Beckman Instruments, Colberg-Poley et al.,
1998).
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